• Please log in or register to access this feature.

Ankylosing Spondylitis

You have full text access to this OnlineOpen article

Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: Results from a randomized, placebo-controlled trial†

  1. Atul Deodhar1,‡,*,
  2. Jürgen Braun2,§,
  3. Robert D. Inman3,¶,
  4. Michael Mack4,‖,
  5. Shreekant Parasuraman5,‖,
  6. Jacqueline Buchanan5,‖,
  7. Benjamin Hsu4,‖,
  8. Tim Gathany5,‖,
  9. Désirée van der Heijde6,††

Article first published online: 2 SEP 2010

DOI: 10.1002/acr.20233

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 62, Issue 9, pages 1266–1271, September 2010

Additional Information

How to Cite

Deodhar, A., Braun, J., Inman, R. D., Mack, M., Parasuraman, S., Buchanan, J., Hsu, B., Gathany, T. and van der Heijde, D. (2010), Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: Results from a randomized, placebo-controlled trial. Arthritis Care Res, 62: 1266–1271. doi: 10.1002/acr.20233

Author Information

  1. 1

    Oregon Health & Science University, Portland

  2. 2

    Rheumazentrum Ruhrgebiet, Herne, Germany

  3. 3

    University of Toronto, Toronto, Ontario, Canada

  4. 4

    Centocor Research and Development, Malvern, Pennsylvania

  5. 5

    Johnson & Johnson Pharmaceutical Services, Malvern, Pennsylvania

  6. 6

    Leiden University Medical Center, Leiden, The Netherlands

  1. ‡

    Dr. Deodhar has received payments (more than $10,000) for educational lectures, teleconferences, and serving on advisory boards for Centocor, a company that may have a commercial interest in the results of this research. This potential conflict of interest has been reviewed and man aged by Oregon Health & Science University.

  2. §

    Dr. Braun has received consultancy fees, speaking fees, and/or honoraria (less than $10,000 each) from Centocor, Schering-Plough, Wyeth, Amgen, Abbott, Bristol-Myers Squibb, UCB, Roche, Chugai, Pfizer, and MSD.

  3. Dr. Inman has received consultancy fees, speaking fees, and/or honoraria (less than $10,000 each) from Centocor, Schering-Plough, Abbott, Amgen, Wyeth, and Sanofi-Aventis.

  4. ‖

    Drs. Mack, Parasuraman, and Hsu, Mr. Gathany, and Ms Buchanan have stock ownership or options in Johnson & Johnson.

  5. ††

    Dr. van der Heijde has received consultancy fees, speaking fees, and/or honoraria (less than $10,000 each) from Abbott, Amgen, Centocor, Pfizer, Roche, Schering-Plough, UCB, and Wyeth.

*Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239

  1. †

    ClinicalTrials.gov identifier: NCT00265083.

  2. ‡

    Dr. Deodhar has received payments (more than $10,000) for educational lectures, teleconferences, and serving on advisory boards for Centocor, a company that may have a commercial interest in the results of this research. This potential conflict of interest has been reviewed and man aged by Oregon Health & Science University.

  3. §

    Dr. Braun has received consultancy fees, speaking fees, and/or honoraria (less than $10,000 each) from Centocor, Schering-Plough, Wyeth, Amgen, Abbott, Bristol-Myers Squibb, UCB, Roche, Chugai, Pfizer, and MSD.

  4. Dr. Inman has received consultancy fees, speaking fees, and/or honoraria (less than $10,000 each) from Centocor, Schering-Plough, Abbott, Amgen, Wyeth, and Sanofi-Aventis.

  5. ‖

    Drs. Mack, Parasuraman, and Hsu, Mr. Gathany, and Ms Buchanan have stock ownership or options in Johnson & Johnson.

  6. ††

    Dr. van der Heijde has received consultancy fees, speaking fees, and/or honoraria (less than $10,000 each) from Abbott, Amgen, Centocor, Pfizer, Roche, Schering-Plough, UCB, and Wyeth.

Publication History

  1. Issue published online: 2 SEP 2010
  2. Article first published online: 2 SEP 2010
  3. Accepted manuscript online: 21 APR 2010 12:00AM EST
  4. Manuscript Accepted: 5 APR 2010
  5. Manuscript Received: 15 OCT 2009

Funded by

  • Centocor Research and Development and the Schering-Plough Research Institute

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (153K)

REFERENCES

  • 1
    Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006; 54: 569–78.
    Direct Link:
  • 2
    Calin A, Edmunds L, Kennedy LG. Fatigue in ankylosing spondylitis: why is it ignored? J Rheumatol 1993; 20: 991–5.
  • 3
    Dagfinrud H, Vollestad NK, Loge JH, Kvien TK, Mengshoel AM. Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 2005; 53: 5–11.
    Direct Link:
  • 4
    Revicki DA, Luo MP, Wordsworth P, Wong RL, Chen N, Davis JC Jr. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 2008; 35: 1346–53.
  • 5
    Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis: progress at OMERACT 7. J Rheumatol 2005; 32: 2250–6.
  • 6
    Hultgren S, Broman JE, Gudbjornsson B, Hetta J, Lindqvist U. Sleep disturbances in outpatients with ankylosing spondylitis questionnaire study with gender implications. Scand J Rheumatol 2000; 29: 365–9.
  • 7
    Gudbjornsson B, Broman JE, Hetta J, Hallgren R. Sleep disturbances in patients with primary Sjögren's syndrome. Br J Rheumatol 1993; 32: 1072–6.
  • 8
    Karapolat H, Akkoc Y, Sari I, Eyigor S, Akar S, Kirazli Y, et al. Comparison of group-based exercise versus home-based exercise in patients with ankylosing spondylitis: effects on Bath Ankylosing Spondylitis Indices, quality of life and depression. Clin Rheumatol 2008; 27: 695–700.
  • 9
    Carr-Hill RA, Kind P. The Nottingham health profile [letter]. Soc Sci Med 1989; 28: 885.
  • 10
    Gunaydin R, Goksel Karatepe A, Cesmeli N, Kaya T. Fatigue in patients with ankylosing spondylitis: relationships with disease-specific variables, depression, and sleep disturbance. Clin Rheumatol 2009; 28: 1045–51.
  • 11
    Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193–213.
  • 12
    Inman RD, Davis JC Jr, van der Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 3402–12.
    Direct Link:
  • 13
    Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol 1988; 41: 313–21.
  • 14
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286–91.
  • 15
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281–5.
  • 16
    Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36) I. Conceptual framework and item selection. Med Care 1992; 30: 473–83.
  • 17
    Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute; 1994.
  • 18
    Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology [editorial]. J Rheumatol 1998; 25: 198–9.
  • 19
    Nasermoaddeli A, Sekine M, Kumari M, Chandola T, Marmot M, Kagamimori S. Association of sleep quality and free time leisure activities in Japanese and British civil servants. J Occup Health 2005; 47: 384–90.
View Full Article (HTML) Get PDF (153K)